Background/Aim: Late toxicity and long-term outcomes of a phase I-II trial on patients with prostate cancer treated with an integrated boost to the dominant intraprostatic lesion (DIL) are reported. Patients and Methods: Patients were treated using intensity-modulated radiotherapy, with a simultaneous integrated boost to the DIL, defined on staging magnetic resonance imaging, delivering 72 Gy in 1.8 Gy/fraction to prostate/seminal vesicles and 80 Gy in 2 Gy/fraction to the DIL. The primary endpoint was acute toxicity and secondary endpoints were late toxicity and biochemical disease-free survival. Results: Forty-four patients were enrolled. The median follow-up was 120 (range=25-150) months. Five-year rates of grade 3 late gastrointestinal and genitourinary toxicity were 2.3% and 4.5%, respectively; only one grade 4 late genitourinary toxicity was recorded. Five-year biochemical relapse-free and overall survival rates were 95.3% and 95.5%, respectively. Conclusion: The treatment was well tolerated and achieved excellent results in terms of outcome in patients with low-intermediate Gleason’s score and low risk of nodal metastasis.

Buwenge, M., Alitto, A. R., Cilla, S., Capocaccia, I., Mazzeo, E., Ippolito, E., Mantini, G., Siepe, G., Cavallini, L., Valentini, V., Deodato, F., Morganti, A. G., Macchia, G., Simultaneous integrated radiotherapy boost to the dominant intraprostatic lesion: Final results of a phase I/II trial, <<ANTICANCER RESEARCH>>, 2020; 40 (11): 6499-6503. [doi:10.21873/anticanres.14672] [http://hdl.handle.net/10807/207163]

Simultaneous integrated radiotherapy boost to the dominant intraprostatic lesion: Final results of a phase I/II trial

Alitto, A. R.;Cilla, S.;Mantini, G.;Valentini, V.;Deodato, F.;Morganti, A. G.;Macchia, G.
2020

Abstract

Background/Aim: Late toxicity and long-term outcomes of a phase I-II trial on patients with prostate cancer treated with an integrated boost to the dominant intraprostatic lesion (DIL) are reported. Patients and Methods: Patients were treated using intensity-modulated radiotherapy, with a simultaneous integrated boost to the DIL, defined on staging magnetic resonance imaging, delivering 72 Gy in 1.8 Gy/fraction to prostate/seminal vesicles and 80 Gy in 2 Gy/fraction to the DIL. The primary endpoint was acute toxicity and secondary endpoints were late toxicity and biochemical disease-free survival. Results: Forty-four patients were enrolled. The median follow-up was 120 (range=25-150) months. Five-year rates of grade 3 late gastrointestinal and genitourinary toxicity were 2.3% and 4.5%, respectively; only one grade 4 late genitourinary toxicity was recorded. Five-year biochemical relapse-free and overall survival rates were 95.3% and 95.5%, respectively. Conclusion: The treatment was well tolerated and achieved excellent results in terms of outcome in patients with low-intermediate Gleason’s score and low risk of nodal metastasis.
Inglese
Buwenge, M., Alitto, A. R., Cilla, S., Capocaccia, I., Mazzeo, E., Ippolito, E., Mantini, G., Siepe, G., Cavallini, L., Valentini, V., Deodato, F., Morganti, A. G., Macchia, G., Simultaneous integrated radiotherapy boost to the dominant intraprostatic lesion: Final results of a phase I/II trial, <<ANTICANCER RESEARCH>>, 2020; 40 (11): 6499-6503. [doi:10.21873/anticanres.14672] [http://hdl.handle.net/10807/207163]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/207163
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 2
social impact